Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Demeclocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | USP2 | O75604 | 5/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CASP7 | P55210 | 1/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demeclocycline SCHEMBL20716691 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL20952687 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL3252 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL3253 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL5503953 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL2636809 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL29355123 | 1.00 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL29487284 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL6549174 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 | |
| Demeclocycline SCHEMBL41287 | 0.99 | MEN1 (0.71) | MEN1KMT2ATDP1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-7820641-B2 | Bactericides; antitumor agents; moderators of gene expression; viricides; parasiticides; malaria therapy | PARATEK PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | TBCA, TUBB6, TUBB | MEN1 3697/4885KMT2A 3257/4885TDP1 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.